Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer

PURPOSE: A proportion of patients with metastatic colorectal cancer (mCRC) are still able to continue with active therapy after their progression to fluoropyrimidines, oxaliplatin, and irinotecan regimens. Studies suggest that gemcitabine and fluoropyrimidines are synergic antimetabolites. The purpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez-Fonseca, P., Solis, M. P., Garrido, M., Faez, L., Rodriguez, D., Ruiz, A. L., Sanchez Lorenzo, M. L., Uriol, E., Menendez, M. D., Viéitez, J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544491/
https://www.ncbi.nlm.nih.gov/pubmed/25428757
http://dx.doi.org/10.1007/s12094-014-1243-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544491/
https://www.ncbi.nlm.nih.gov/pubmed/25428757
http://dx.doi.org/10.1007/s12094-014-1243-1

Ejemplares similares